A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Phase 1
234
about 3.9 years
18–75
2 sites in FL, VA
What this study is about
This trial is testing a treatment called ALK202 for people with advanced solid tumors. The goal is to see if it's safe, well-tolerated, how the body processes it (pharmacokinetics), and whether it fights cancer cells (antitumor activity).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ALK202
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: To evaluate the safety and tolerability of ALK202 in adult participants with advanced solid tumors; To determine the maximum tolerated dose (MTD); To determine the recommended dose(s) of ALK202 for subsequent clinical studies.
Secondary: To evaluate the pharmacokinetics (PK) of ALK202
Oncology